Overweight, Obesity
Conditions
Brief summary
The study looks at the blood levels of a new study medicine in people with normal and impaired kidney function. Participants will get the study medicine called NNC0174-0833. This is an experimental medicine and has not been approved by the US FDA. It is being developed as a new medicine for weight management. Participants will get 1 injection of the study medicine by a study nurse at the clinic. The injection will be with a needle in a skin fold in the stomach area. The study will last for about 9 weeks. Participants will have about 7 visits with the study staff or the doctor. At the visits, participants will have clinical checks done and blood samples taken. Participants will be collecting their urine several times during the study. Participants will be asked about their health, medical history and habits. People who are already in another research study cannot take part. Only women who are not able to become pregnant can take part in the study. Only men who do not plan to father a child during the study or 6 weeks following the dose administration can take part in the study.
Interventions
DRUGNNC0174-0833
A single subcutaneous (s.c., under the skin) dose of 0.6 mg NNC0174-0833.
Sponsors
Novo Nordisk A/S
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
* Male or female of non-childbearing potential, aged 18-80 years (both inclusive) at the time of signing informed consent. * Meeting the pre-defined GFR criteria using estimated GFR (eGFR) based on serum creatinine for any of the renal function groups: * For subjects with normal renal function: eGFR of equal to or above 90 mL/min * For patients with mild renal impairment: eGFR of 60-89 mL/min * For patients with moderate renal impairment: eGFR of 30-59 mL/min * For patients with severe renal impairment: eGFR of \<30 mL/min not requiring dialysis
Exclusion criteria
* Any disorder, which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol. * Use of prescription or non-prescription drugs, or non-routine vitamins, which at the investigators judgement may affect subject safety or the results of the trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Area under the plasma NNC0174-0833 concentration-time curve after a single dose | From baseline (Visit 2, Day 1, pre-dose) until completion of the end of trial visit (Visit 7, Day 36) | nmol\*h/L |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Maximum observed plasma NNC0174-0833 concentration after a single dose | From baseline (Visit 2, Day 1, pre-dose) until completion of the end of trial visit (visit 7, Day 36) | nmol/L |
| Time to maximum observed plasma NNC0174-0833 concentration after a single dose | From baseline (Visit 2, Day 1, pre-dose) until completion of the end of trial visit (Visit 7, Day 36) | hours |
| Number of treatment emergent adverse events (TEAEs) | From time of trial product administration (Visit 2, Day 1) until completion of the end of trial visit (Visit 7, Day 36) | Number of events |
Countries
United States
Outcome results
None listed